Errata - English

PDF CSV October 18, 2023 through October 18, 2025 All Errata for USP–NF How to use
Enter the title of the monograph
Monograph Title Section Source Publication Page Number Errata Post Date Errata Official Date Target Errata Print Publication Target Online Fix Publication Description
DIPHENHYDRAMINE CITRATE AND IBUPROFEN TABLETS IMPURITIES/Limit of Ibuprofen Related Compound C USP37–NF32 2651 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 7 of Analysis: Change
RU = peak area ratio of ibuprofen to valerophenone from the Sample solution
RS = peak area ratio of ibuprofen to valerophenone from the Standard solution
to:
RU = peak area ratio of… Read More
DOXEPIN HYDROCHLORIDE ORAL SOLUTION ASSAY/Procedure USP37–NF32 2713 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 1 of Standard solution: Change
Dilute 4.0 of Standard stock solution
to:
Dilute 4.0 mL of Standard stock solution
ESCITALOPRAM TABLETS PERFORMANCE TESTS/Dissolution <711>/Test 2 USP37–NF32 2852 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 3 of Buffer: Change
phosphoric
to:
phosphoric acid
FOSPHENYTOIN SODIUM INJECTION ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP37–NF32 3096 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Before USP Fosphenytoin Sodium RS: Add
USP Endotoxin RS
GADOPENTETATE DIMEGLUMINE INJECTION IDENTIFICATION/B. USP37–NF32 3113 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 2: Change
364.8 nm
to:
368.4 nm
GRISEOFULVIN CAPSULES PERFORMANCE TESTS/Uniformity of Dosage Units <905>/Procedure for content uniformity USP37–NF32 3196 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 6 of Analysis: Change
Result = (AU/AS) × (CS/CU) × P × 100
to:
Result = (AU/AS) × (CS/CU) × P × F × 100
AND… Read More
GRISEOFULVIN TABLETS ASSAY/Procedure USP37–NF32 3198 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 13 of Analysis: Change
P = potency of griseofulvin in USP Griseofulvin RS (μg/mL)
to:
P = potency of griseofulvin in USP Griseofulvin RS (μg/mg)
HEXACHLOROPHENE LIQUID SOAP IDENTIFICATION/B. USP37–NF32 3231 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 1 of Analysis: Change
Sample solution
to:
Sample
HYDROCHLOROTHIAZIDE TABLETS IMPURITIES/Organic Impurities USP37–NF32 3247 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 11 of Analysis: Change
CU = concentration of the Sample solution (μg/mL)
to:
CU = nominal concentration of hydrochlorothiazide in the Sample solution (μg/mL)
STRONG IODINE SOLUTION ASSAY USP37–NF32 3354 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 1 of Acceptance criteria in Iodine: Change
of iodine (I)
to:
of iodine (I) in each 100 mL
AND
Line 1 of Acceptance criteria in Potassium Iodide: Change
potassium iodide (KI)
to:
potassium iodide (KI) in each 100 mL
LAMIVUDINE AND ZIDOVUDINE TABLETS IMPURITIES/Organic Impurities USP37–NF32 3484 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 12 of Analysis: Change
unidentified impurity
to:
unspecified impurity
AND
Line 19 of Analysis: Change
unidentified impurities
to:
unspecified impurities
LINDANE CREAM ASSAY/Procedure/Chromatographic system/Temperatures USP37–NF32 3561 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 After the Injection port subsection: Add a new subsection
Detector: 250°
MAPROTILINE HYDROCHLORIDE TABLETS PERFORMANCE TESTS/Dissolution <711> USP37–NF32 3655 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 3 of Analysis: Change
Determine the labeled amount of maprotiline hydrochloride
to:
Determine the percentage of the labeled amount of maprotiline hydrochloride
METHADONE HYDROCHLORIDE ORAL SOLUTION OTHER COMPONENTS USP37–NF32 3744 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 3 of Alcohol Determination: Change
gas–liquid chromatographic procedure
to:
gas chromatographic procedure
MICONAZOLE INJECTION IDENTIFICATION/A./Chromatographic system USP37–NF32 3831 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 1 of Spray reagent: Change
(Dragendorff’s reagent)
to:
(Dragendorff’s TS)
NYSTATIN DEFINITION USP37–NF32 4035 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 6: Change
extemporaneous solution
to:
extemporaneous preparation
OLMESARTAN MEDOXOMIL CHEMICAL INFORMATION USP37–NF32 4057 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 3 of the chemical name: Change
methyl ester
to:
methyl ester;
(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-{[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate
OMEPRAZOLE ORAL SUSPENSION ASSAY/Procedure USP37–NF32 4067 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 2 of Solution A: Change
with dilute phosphoric acid
to:
with dilute sodium hydroxide
OXCARBAZEPINE TABLETS IMPURITIES USP37–NF32 4119 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Row 5 of Column 1 of Table 1: Change
Methoxydibenzazepineb
to:
Methoxycarbamazepineb
OXCARBAZEPINE TABLETS PERFORMANCE TESTS/Dissolution <711>/Test 2 USP37–NF32 4119 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 4 of Standard solution: Change
µg/mL, where L is the label claim in mg/Tablet.
to:
mg/mL, where L is the label claim in mg/Tablet.
PROGESTERONE VAGINAL SUPPOSITORIES ASSAY/Suppositories in Fatty Acid Base USP37–NF32 4430 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 1 of System suitability solution: Change
Transfer 2.0 mL of System suitability stock solution A and System suitability stock solution B
to:
Transfer 2.0 mL of each System suitability stock solution A and System suitability stock solution B
AND… Read More
PSEUDOEPHEDRINE HYDROCHLORIDE, CARBINOXAMINE MALEATE, AND DEXTROMETHORPHAN HYDROBROMIDE ORAL SOLUTION Microbial enumeration tests <61> and Tests for specified microorganisms <62> USP37–NF32 4486 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 3: Change
does not exceed 100 per g, the total combined molds and yeasts count does not exceed 10 per g,
to:
does not exceed 102 cfu/g, the total combined molds and yeasts count does not exceed 101 cfu/g,
PYRANTEL PAMOATE ASSAY/Procedure USP37–NF32 4491 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 1 of Mobile phase: Change
acetic acid
to:
glacial acetic acid
AND
Line 1 of Column efficiency: Change
NLT 8000 theoretical plates
to:
NLT 8000 theoretical plates for the pyrantel peak
PYRANTEL PAMOATE OTHER COMPONENTS/Content of Pamoic Acid USP37–NF32 4491 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 1 of Mobile phase: Change
acetic acid
to:
glacial acetic acid
PYRAZINAMIDE Identification/B: Ultraviolet Absorption <197U> USP37–NF32 4493 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 4: Change
on the dried basis
to:
on the anhydrous basis
QUINIDINE GLUCONATE DEFINITION USP37–NF32 4512 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 6: Change
quinidine sulfate
to:
quinidine gluconate
QUINIDINE GLUCONATE EXTENDED-RELEASE TABLETS ASSAY/Procedure USP37–NF32 4515 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 2 of System suitability solution: Change
dihydroquinidine chloride
to:
dihydroquinidine hydrochloride
RIBAVIRIN CAPSULES PERFORMANCE TESTS/Dissolution <711>/Procedure 1/Chromatographic system USP37–NF32 4562 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 1 of Column: Change
7-µm packing L17
to:
9-µm packing L17
RITONAVIR IMPURITIES USP37–NF32 4601 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Row 13 of Column 1 of Table 2: Change
3-Epimerm
to:
3R-Epimerm
AND
Row 16 of Column 1 of Table 2: Change
5-Epimerp
to:
5R-Epimerp
AND
Row 17 of Column 1 of Table 2: Change
Valine urea… Read More
SODIUM SALICYLATE ASSAY/Procedure USP37–NF32 4727 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 1 of Blank: Change
acetic acid
to:
glacial acetic acid
SUFENTANIL CITRATE INJECTION ASSAY/Procedure USP37–NF32 4759 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 11 of Analysis: Change
sufentanil
to:
sufentanil citrate
SULFACETAMIDE SODIUM OPHTHALMIC OINTMENT ASSAY/Procedure USP37–NF32 4765 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 1 of Sample solution: Change
USP Sulfacetamide Sodium RS
to:
sulfacetamide sodium
SULFACETAMIDE SODIUM OPHTHALMIC SOLUTION ASSAY/Procedure USP37–NF32 4766 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 2 of Sample stock solution: Change
sulfacetamide
to:
sulfacetamide sodium
AND
Line 1 of Sample solution: Change
sulfacetamide
to:
sulfacetamide sodium
TAMSULOSIN HYDROCHLORIDE CAPSULES PERFORMANCE TESTS/Dissolution <711>/Test 4 USP37–NF32 4830 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 9 of the second calculation: Change
V = volume of Buffer stage medium, 1000 mL
to:
V = volume of Buffer stage medium, 500 mL
THIOTHIXENE Limit of (E)-thiothixene/Standard preparations USP37–NF32 4942 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 1 of C: Change
Transfer about 200 mg of thiothixene
to:
Transfer about 200 mg of Thiothixene
TRIACETIN ASSAY/Procedure/Titrimetric system USP37–NF32 5031 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 2: Change
(See Titrimetry <541>, Residual Titrations.)
to:
(See Titrimetry <541>.)
AND
Line 1 of Mode: Change
Direct titration
to:
Residual titration
VALSARTAN IMPURITIES USP37–NF32 5115 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Footnote a of Table 1: Change
(S)-N-Butyryl-N-([2′-(1H-tetrazole-5-yl)biphen-4-yl]methyl)-valine.
to:
N-Butyryl-N-{[2′-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}-L-valine.
AND
Footnote b of Table 1: Change
(S)-… Read More
VALSARTAN ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP37–NF32 5115 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 2 of USP Valsartan Related Compound A RS: Change
(R)-N-Valeryl-N-([2′-(1H-tetrazole-5-yl)biphen-4-yl]methyl)valine.
to:
N-Valeryl-N-{[2′-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}-D-valine.
AND
Line 2 of USP Valsartan Related… Read More
ECHINACEA ANGUSTIFOLIA ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP37–NF32 5343 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 5: Change
USP Powdered Echinacea purpurea Extract RS
to:
USP Powdered Echinacea angustifolia Extract RS
POWDERED ECHINACEA ANGUSTIFOLIA ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP37–NF32 5346 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 5: Change
USP Powdered Echinacea purpurea Extract RS
to:
USP Powdered Echinacea angustifolia Extract RS
POWDERED ECHINACEA ANGUSTIFOLIA EXTRACT ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP37–NF32 5350 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 5: Change
USP Powdered Echinacea purpurea Extract RS
to:
USP Powdered Echinacea angustifolia Extract RS
ECHINACEA PALLIDA ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP37–NF32 5353 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 5: Change
USP Powdered Echinacea purpurea Extract RS
to:
USP Powdered Echinacea pallida Extract RS
POWDERED ECHINACEA PALLIDA ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP37–NF32 5356 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 5: Change
USP Powdered Echinacea purpurea Extract RS
to:
USP Powdered Echinacea pallida Extract RS
POWDERED ECHINACEA PALLIDA EXTRACT ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP37–NF32 5359 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 5: Change
USP Powdered Echinacea purpurea Extract RS
to:
USP Powdered Echinacea pallida Extract RS
POWDERED ECHINACEA PURPUREA EXTRACT COMPOSITION USP37–NF32 5371 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 14 of Analysis in Content of Total Phenols: Change
CS = concentration of the relevant analyte in the corresponding Standard solution
CU = concentration of Echinacea purpurea in the Sample solution (mg/mL)
to:… Read More
POWDERED DECAFFEINATED GREEN TEA EXTRACT COMPOSITION/Content of Polyphenols/Chromatographic system USP37–NF32 5438 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 1 of Column: Change
4.6-mm 6 25-cm;
to:
4.6-mm × 25-cm;
POWDERED DECAFFEINATED GREEN TEA EXTRACT SPECIFIC TESTS USP37–NF32 5438 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 5 of Analysis in Limit of Gallic Acid: Change
Separately calculate the percentages of gallic acid
to:
Calculate the percentage of gallic acid
AND
Line 5 of Analysis in Limit of Caffeine: Change
Separately calculate the percentages of caffeine
… Read More
HOLY BASIL LEAF COMPOSITION/Content of Triterpenes USP37–NF32 5454 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 4 of Standard solution B: Change
0.45-μL
to:
0.45-μm
POWDERED HOLY BASIL LEAF COMPOSITION/Content of Triterpenes USP37–NF32 5456 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 4 of Standard solution B: Change
0.45-μL
to:
0.45-μm
POWDERED HOLY BASIL LEAF EXTRACT COMPOSITION/Content of Triterpenes USP37–NF32 5458 30-May-2014 1-Jun-2014 USP38–NF33 USP38–NF33 Line 4 of Standard solution B: Change
0.45-μL
to:
0.45-μm